Document Classification

Section Type: RESULTS

Text: The 100 mg dose demonstrated a significant effect versus placebo on DAS28-CRP < 2. 6 (23. 1 % vs 6. 7 %, p = 0. 016), all categories of the American College of Rheumatology (ACR) criteria (ACR20 : 69. 2 % vs 40. 0 %, p = 0. 005 ; ACR50 : 30. 8 % vs 12. 0 %, p = 0. 021 ; ACR70 : 17. 9 % vs 4. 0 %, p = 0. 030), and the Health Assessment Questionnaire Disability Index (-0. 48 vs -0. 25, p = 0. 005).